Ryvu Therapeutics Reports 2023 Half-Year Financial Results and Provides Corporate Update
The total operating revenues amounted to $7.9M and increased by 131% compared to H1 2022. Updated clinical and preclinical data on RVU120 were presented at the European Hematology Associated (EHA) Congress in June 2023. Preparation for the execution of …